uniQure (NASDAQ:QURE) Sets New 1-Year High – Here’s What Happened

uniQure (NASDAQ:QURE) shares hit a new 52-week high on Tuesday . The company traded as high as $19.00 and last traded at $18.88, with a volume of 109599 shares changing hands. The stock had previously closed at $18.08.

Analysts Set New Price Targets

Several brokerages have recently issued reports on QURE. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 10th. Royal Bank of Canada upped their price objective on uniQure from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Cantor Fitzgerald raised their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 10th. Finally, Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus target price of $33.88.

uniQure Stock Up 1.4 %

The stock has a 50-day moving average price of $10.38 and a 200-day moving average price of $7.66. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company has a market capitalization of $893.46 million, a P/E ratio of -3.70 and a beta of 0.41.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, research analysts predict that uniQure will post -3.82 EPS for the current fiscal year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now directly owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.74% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QURE. Point72 Asset Management L.P. raised its position in uniQure by 336.1% in the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after acquiring an additional 752,889 shares during the period. Walleye Capital LLC purchased a new stake in shares of uniQure during the 3rd quarter worth approximately $444,000. FMR LLC lifted its stake in uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Franklin Resources Inc. bought a new position in uniQure during the third quarter valued at $7,360,000. Finally, Y Intercept Hong Kong Ltd bought a new position in uniQure during the third quarter valued at $283,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.